CoChat
Sign Up
Cited by 287Gastrointestinal motility and disordersProbiotics and Fermented FoodsGut microbiota and health

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life -- a double-blind, placebo-controlled study: Randomised clinical trial: B. bifidum MIMBb75 in IBS

Open access
Guglielmetti, S., Mora, D., Gschwender, M., Popp, K.·2011·Alimentary Pharmacology & Therapeutics
DOI 10.1111/j.1365-2036.2011.04633.x
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (IBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest. AIM: To assess the efficacy of Bifidobacterium bifidum MIMBb75 in IBS. METHODS: A total of 122 patients were randomised to receive either placebo (N=62) or MIMBb75 (N=60) once a day for 4 weeks. The severity of IBS symptoms was recorded daily on a 7-point Likert scale. RESULTS: MIMBb75 significantly reduced the global assessment of IBS symptoms by -0.88 points (95% CI: -1.07; -0.69) when compared with only -0.16 (95% CI: -0.32; 0.00) points in the placebo group (P<0.0001). MIMBb75 also significantly improved the IBS symptoms pain/discomfort, distension/bloating, urgency and digestive disorder. The evaluation of the SF12 sum scores showed a significant gain in quality of life within the bifidobacteria group. Furthermore, adequate relief was reported by 47% of the patients in the bifidobacteria and only by 11% of the patients in the placebo group (P<0.0001). Overall responder rates were 57% in the bifidobacteria group but only 21% in the placebo group (P=0.0001). MIMBb75 was well tolerated and adverse events were not different from placebo. CONCLUSIONS: Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life. Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2011.04633.x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 16 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    The study population had mild to moderate IBS symptoms, as shown by baseline SGA values.

    “The study population has mild to moderate IBS symptoms as evidenced by the indicated SGA-baseline values.”
    Quote in the paperNot a substantial claim
  • Findingown data

    The improvement in bowel movement satisfaction persisted during wash-out: 2.33 with MIMBb75 versus 3.47 with placebo, P<0.0001.

    “The reduction persisted during wash-out phase (2.33 in the bifidobacteria group vs. 3.47 in the placebo group, P < 0.0001).”
    Quote in the paperSubstantial claim
  • Findingown data

    MIMBb75 reduced distension/bloating during treatment by 0.92 points (95% CI 1.15 to 0.69), versus 0.21 points (95% CI 0.37 to 0.05) for placebo, P<0.0001.

    “and distension ⁄ bloating by )0.92 points (95% CI: )1.15; )0.69) vs. )0.21(95% CI: )0.37; )0.05) in the placebo group (P < 0.0001) during the treatment.”
    Quote in the paperSubstantial claim
  • Findingown data

    Weekly SGA analysis showed a significant benefit for MIMBb75 in every week from the second treatment week through the end of the study.

    “The evaluation of the SGA on a weekly basis showed a significant benefit for patients within the bifidobacteria group for every single week starting the second week of treatment till the end of the study (Figure 3).”
    Quote in the paperNot a substantial claim
  • Findingown data

    No severe adverse events occurred in either group.

    “Additionally, no severe adverse events have been recorded in either group.”
    Quote in the paperNot a substantial claim
  • May combine two claims. 28
  • The quote only partly states this claim. 2
  • Classified as probably not a substantial claim. 11

  • May combine two claims.

    Findingown data

    Bowel movement satisfaction (digestive disorder) fell from 3.89 to 2.44 with MIMBb75 versus 3.69 to 3.47 with placebo after treatment, P=0.0002.

    “Bowel movement satisfaction (digestive disorder) decreased from 3.89 to 2.44 in the bifidobacteria group vs. 3.69 to 3.47 in the placebo group (P = 0.0002) after treatment.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Overall responder rates were 57% with MIMBb75 and 21% with placebo, P=0.0001.

    “Overall responder rates were 57% in the bifidobacteria group and only 21% in the placebo group (P = 0.0001).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    At the end of treatment, adequate relief was achieved by 43% of MIMBb75 patients and 8% of placebo patients, P<0.0001.

    “At the end of treatment, 43% of the patients in the bifidobacteria group achieved adequate relief compared with only 8% in the placebo group (P < 0.0001).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Suspected treatment-related adverse events numbered 36 overall (13 placebo, 23 MIMBb75), with no significant difference in side-effect profile between groups.

    “Only 36 adverse events were reported with suspected relation to the study product, 13 in the placebo and 23 in the treatment group, but no significant differences could be detected in the side-effects profile of B. bifidum MIM-Bb75 vs. placebo”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    MIMBb75 reduced urgency during treatment by 0.67 points (95% CI 0.86 to 0.48), versus 0.21 points (95% CI 0.35 to 0.07) for placebo, P=0.0001; this reduction was not present during wash-out.

    “Urgency was significantly reduced by )0.67 points (95% CI: )0.86; )0.48) vs. )0.21(95% CI: )0.35; )0.07) in the placebo group (P = 0.0001) during the treatment but not during the wash-out phase.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    In adults with mild-to-moderate IBS, four weeks of MIMBb75 reduced the global IBS symptom score from baseline by 0.88 points (95% CI 1.07 to 0.69), compared with 0.16 points (95% CI 0.32 to 0.00) for placebo, with P<0.0001.

    “MIMBb75 significantly reduced the global assessment of IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) when compared with only )0.16 (95% CI: )0.32; 0.00) points in the placebo group (P < 0.0001).”
    • Also stated in: § Bifidobacterium bifidum · plain
      “MIMBb75 significantly improved global IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) (from 2.95 in the run in phase to 2.07 in the treatment phase) compared with only )0.16 points (95% CI: )0.32; 0.00) (from 2.79 in the run in phase to 2.63 in the treatment phase) in the placebo group (P < 0.0001) using the 7-point Likert scale.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    MIMBb75 reduced pain/discomfort during treatment by 0.82 points (95% CI 1.01 to 0.63), versus 0.18 points (95% CI 0.35 to 0.01) for placebo, P<0.0001.

    “Bifidobacterium bifidum MIMBb75 showed a significant reduction of pain ⁄ discomfort by )0.82 points (95% CI: )1.01; )0.63) vs. )0.18(95% CI: )0.35; )0.01) in the placebo group (P < 0.0001)”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    No treatment effect was detected for bowel movement frequency or feeling of incomplete bowel evacuation.

    “No effects could be detected for frequency of bowel movement and feeling of incomplete bowel evacuation (Figure 4).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    Pain/discomfort responder rates were 48% with MIMBb75 and 24% with placebo, P=0.008.

    “The difference between the treatment arms was only a little bit less pronounced when considering only the symptom 'pain ⁄ discomfort' where responder rates were calculated to be 48% in the bifidobacteria and only 24% in the placebo group (P = 0.008)”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    The SF-12 physical health sum changed by 3.99 points with MIMBb75 and 1.08 points with placebo from baseline, P=0.0185.

    “Physical health sum significantly changed by 3.99 in the bifidobacteria group and by only 1.08 in the placebo group compared with baseline (P = 0.0185).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    The SF-12 mental health sum changed by 5.78 points with MIMBb75 and 1.58 points with placebo from baseline, P=0.0083.

    “Mental health sum significantly changed by 5.78 in the bifidobacteria group and by only 1.58 in the placebo group compared with baseline (P = 0.0083).”
    Quote in the paperSubstantial claim

  • May combine two claims. The quote only partly states this claim.

    Findingown data

    Reductions in pain/discomfort and distension/bloating persisted during the wash-out phase.

    “The reduction persisted during the wash-out phase.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    Of 132 included patients, 122 were randomised (62 placebo, 60 MIMBb75) and all randomised patients were analysed for intent to treat.

    “A total of 132 patients were included into the study and 122 patients were successfully randomised to receive either placebo (N = 62) or B. bifidum MIMBb75 (N = 60).All randomised patients were analysed for intent to treat (N = 122).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Study design and conductown data

    The primary analysis used the intent-to-treat population, with missing post-baseline values imputed by baseline and counted as nonresponders; a per-protocol analysis was supportive.

    “The primary analysis was based on the intent-to-treat population where all successfully randomised patients were included.Missing post-baseline values were imputed by the baseline value for the primary target criterion and these patients were evaluated as nonresponders”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    The primary efficacy variable was prospectively defined as the subject's global assessment of IBS symptoms on a 7-point Likert scale.

    “The prospectively defined primary efficacy variable was the subject's global assessment of IBS symptoms using a 7-point Likert scale.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    Patients were allocated 1:1 using a computer-generated blocked randomisation list with block size 4.

    “The treatment was allocated according to a computer-generated blocked randomisation list with a block size of 4.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    The study was prospective, multi-centre, randomised, double-blind, placebo-controlled, and two-arm.

    “This study was performed as a prospective, multi-centre, randomised, double-blind, placebo-controlled, two-arm nutritional study.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductreasoning

    Sample size was calculated from published data assuming a 0.6-point SGA difference, SD 1.0, two-sided alpha 0.05, and 80% power, requiring 47 patients per group; 110 were planned and 132 recruited.

    “Based on published data, 17 a difference of 0.6 points in the SGA of IBS symptoms between B. bifidum MIMBb75 and placebo on the 7-point Likert scale was anticipated”
    • Also stated in: § Sample size estimation. · plain
      “With these assumptions, a Wilcoxon-Mann-Whitney test with a two-sided significance level of a = 0.05 and a power of 1)b = 0.8, a sample size of 47 patients per group was required.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [17] Whorwell, 2006, Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    The block size was not disclosed to investigators.

    “The block size was not disclosed to the investigators.”
    Quote in the paperNot a substantial claim

  • May combine two claims. The quote only partly states this claim.

    Study design and conductown data

    Baseline characteristics and demographics did not differ significantly between treatment groups.

    “In terms of baseline characteristics, there were no significant differences between the groups”
    • Also stated in: § Baseline characteristics · boosted
      “Demographics were well balanced between the treatment groups”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Several studies have found altered intestinal microbiota with reduced bifidobacteria and a dysfunctional intestinal barrier in IBS patients.

    “Several studies have observed altered intestinal microbiota with a significant lack of bifidobacteria 25,26 and a dysfunctional intestinal barrier in IBS patients.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [25] Kerckhoffs, 2009, Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J Gastroenterol source

      Not checked in the free run.

    • cites [26] Si, 2004, Intestinal microecology and quality of life in irritable bowel syndrome patients, World J Gastroenterol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The surface protein BopA is directly involved in adhesion to Caco-2 cells.

    “Guglielmetti et al. showed that BopA, a surface protein, is directly involved in the adhesion to Caco-2 cells.15”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    BopA is found in several strongly adherent B. bifidum strains, suggesting it may indicate strong adherence.

    “BopA has been found in several strong adhesive B. bifidum strains, indicating that BopA might be an indicator of strong adherence.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    A systematic review included 16 RCTs; only one Bifidobacterium strain showed efficacy in two appropriately designed studies.

    “A total of 16 RCTs were included in the analysis.Of those, exclusively one Bifidobacterium strain showed efficacy for the improvement of IBS symptoms in two appropriately designed studies.4”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [4] Brenner, 2009, The utility of probiotics in the treatmet of irritable bowel syndrome: a systematic review, Am J Gastroenterol source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data

    Given its high efficacy and good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.

    “Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.

  • May combine two claims.

    Interpretationown data

    MIMBb75 significantly improved global IBS and related symptoms such as pain/discomfort, distension/bloating, and digestive disorders compared with placebo.

    “In this study, B. bifidum MIMBb75 significantly improved global IBS as well as its related symptoms such as pain ⁄ discomfort, distension ⁄ bloating and digestive disorders compared with placebo.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    An imbalance of intestinal microbiota and a dysfunctional intestinal barrier may contribute to IBS and its symptoms.

    “Recent research suggests that an imbalance of the intestinal microbiota with a significant reduction of bifidobacteria and a dysfunctional intestinal barrier with subsequent bacterial translocation may contribute to the development of IBS and its symptoms.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [5][6]][7][8][9]

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    B. bifidum MIMBb75 adhesion to Caco-2 monolayers increased with fucose and mannose and decreased when grown in Oxgall bile salts.

    “Additionally B. bifidum MIMBb75 showed considerably more adhesion to the Caco-2 monolayer in the presence of fucose and mannose and less when B. bifidum MIMBb75 grew in Oxgall bile salts compared with standard environmental conditions.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Probiotic efficacy is strongly strain specific, and only certain strains might improve IBS.

    “However, the efficacy of probiotics is strongly strain specific and only certain strains might be able to improve IBS and its symptoms.[12][13][14]”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [12][13][14]

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Gut mucosal barrier disruption is associated with bacterial translocation and inflammatory conditions.

    “Additionally, gut mucosal barrier disruption has been proven to be associated with bacterial translocation and inflammatory conditions.[4][5][6]”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [4][5][6]

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data

    MIMBb75 effectively alleviates global IBS and improves IBS symptoms together with quality of life.

    “Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The colonisation strategy of this bacterium may be influenced by sugars, bile salts, and pH, likely supporting adhesion to distal gut sites.

    “The colonisation strategy of this bacterium could be influenced by several factors varying along the gastrointestinal tract, such as the presence of specific sugars and bile salts and the pH, likely supporting adhesion of B. bifidum MIMBb75 to distal sites of the gut.16”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    An imbalanced microbiota may produce a different fermentation pattern with increased hydrogen, resulting in bloating.

    “It has been stated that the imbalance of the microbiotic composition may lead to a different fermentation pattern, especially with increased hydrogen production resulting in bloating.28,29”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [28] Dear, 2005, Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?, Dig Dis Sci source

      Not checked in the free run.

    • cites [29] Quigley, 2007, Probiotics in irritable bowel syndrome: an immunomodulatory strategy?, J Am Coll Nutr source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Probiotics have been reported to restore intestinal microbiota and gut barrier and to hinder bacterial translocation.

    “As probiotics have been reported in several studies to restore the intestinal microbiota and gut barrier as well as hinder bacterial translocation, the therapeutic potential of probiotics in IBS has become of strong interest.10,11”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [10] Alvares-Olmos, 2001, Probiotic agents and infectious diseases: a modern perspective on a traditional therapy, Clin Infect Dis source

      Not checked in the free run.

    • cites [11] Salminen, 1996, Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges, Antonie Van Leeuwenhoek source

      Not checked in the free run.

34 of 34

  • The paper relies on this without support.

    Conventional medical treatment for IBS is unsatisfactory.

    “As the conventional medical treatment of IBS is unsatisfactory, we have evaluated the efficacy of B. bifidum MIMBb75 in IBS in a double blind, placebo-controlled multi-centre study.”

  • The paper relies on this without support.

    No probiotic strain has yet been shown to significantly alleviate IBS while also improving quality of life.

    “Additionally, to our knowledge, no probiotic strain could show to significantly alleviate irritable bowel syndrome and simultaneously improve the quality of life.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The second study did not detect any effects of the specific probiotic treatment on the frequency of bowel movements and feelings of incomplete evacuation.

    “The second study did not detect any effects of the specific probiotic treatment on the frequency of bowel movements and feelings of incomplete evacuation.56”

    From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]

  • Bifidobacterium bifidum MIMBb75 was beneficial for improving global IBS symptoms, bloating and aspects of health-related quality of life (physical and mental health), but not for frequency of bowel movement and feeling of incomplete bowel evacuation.

    “For example, one study reported that Bifidobacterium bifidum MIMBb75 was beneficial for improving global IBS symptoms, bloating and aspects of health-related quality of life (physical and mental health), but not for frequency of bowel movement and feeling of incomplete bowel evacuation.56”

    From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]

  • In some of the better quality trials bifidobacteria, such as Bifidobacterium infantis 35624, Bifidobacterium lactis DN 173010 and Bifidobacterium bifidum MIMBb75, seem to be advantageous and in others probiotic mixtures appear to be useful.

    “In some of the better quality trials bifidobacteria, such as Bifidobacterium infantis 35624,215 224 241 Bifidobacterium lactis DN 173010208 225 and Bifidobacterium bifidum MIMBb75,226 seem to be advantageous and in others probiotic mixtures appear to be useful.214 229 233”

    From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [226]

  • Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010, Bifidobacterium bifidum MIMBb75, Lactobacillus plantarum 299V, Saccharomyces boulardii, combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07, and multispecies probiotic mixtures.

    “Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010 (74), Bifidobacterium bifidum MIMBb75 (72), Lactobacillus plantarum 299V (117), Saccharomyces boulardii (37), and combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (144) and multispecies probiotic mixtures (71, 87, 88).”

    From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [72]

  • Specific probiotics help reduce bloating/distension in some patients with IBS, with moderate grade of evidence.

    “Specific probiotics help reduce bloating/distension in some patients with IBS Moderate [147,149-150,155-156,168-170, 174-177,179-183]”

    From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K.
Affiliations
University of Milan (IT)
Corresponding author
Guglielmetti, S.
ORCID
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2011-03-21
Volume
33
Issue
10
Pages
1123-1132
ISSN
0269-2813 (ISSN-L)
DOI
10.1111/j.1365-2036.2011.04633.x
OpenAlex
W2142855591
Semantic Scholar
e905099c40db3ed06be733b4cdc354afe771111b
Cited by
287
References
30
Citations by year
2026: 12 · 2025: 8 · 2024: 33 · 2023: 24 · 2022: 24 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 17 · 2016: 12 · 2015: 15 · 2014: 27 · 2013: 21 · 2012: 13
FWCI
22.92
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1625 d)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome, probiotics, quality of life, gut microbiota, intestinal barrier, IBS symptom severity, responder rate, tolerability
MeSH terms
Adult, Bifidobacterium, Double-Blind Method, Female, Humans, Intestines, Male, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-05.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-05.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review